The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

British Journal of Clinical Pharmacology

Volumn 76, Issue 3, 2013, Pages 432-444

  Kasichayanula, Sreeneeranj ^a   Liu, Xiaoni ^a   Pe Benito, Melanie ^a   Yao, Ming ^a   Pfister, Marc ^a   Lacreta, Frank P ^a   Humphreys, William Griffith ^a   Boulton, David W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dapagliflozin; Glucuronosyltransferase; Renal insufficiency; Sodium glucose transporter 2; Type 2 diabetes mellitus; UGT1A9

Indexed keywords

CREATININE; DAPAGLIFLOZIN; DAPAGLIFLOZIN 3 O GLUCURONIDE; DRUG METABOLITE; GLUCOSE; IOHEXOL; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY MICROSOME; LIVER MICROSOME; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE;

DAPAGLIFLOZIN; GLUCURONOSYLTRANSFERASE; RENAL INSUFFICIENCY; SODIUM-GLUCOSE TRANSPORTER 2; TYPE 2 DIABETES MELLITUS; UGT1A9;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSIDES; GLYCOSURIA; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; LIVER; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; YOUNG ADULT;

EID: 84882591638     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12056     Document Type: Article

References (34)

1. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic nephropathy. Diabetes Care 2003; 26: (Suppl. 1): S94-S98.
2. Miller M. Type II diabetes: a treatment approach for the older patient. Geriatrics 1996; 51: 43-49.
3. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
4. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Invest 1994; 93: 397-404.
5. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li VS, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003; 14: 2873-2882.
6. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43.
7. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008; 14: 782-790.
8. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-3434.
9. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
10. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
11. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010; 33: 2217-2224.
12. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
13. Nauck MA, Del PS, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
14. Strojek K, Yoon KH, Hruba B, Elze M, Langkilde AMPS. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938.
15. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012; 66: 446-456.
16. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405-415.
17. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478.
18. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-526.
19. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010; 38: 405-414.
20. Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther 2011; 33: 1798-1808.
21. Krutzen E, Back SE, Nilsson-Ehle P. Determination of glomerular filtration rate using iohexol clearance and capillary sampling. Scand J Clin Lab Invest 1990; 50: 279-283.
22. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. 1998. US FDA Web site. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf (last accessed 24 October 2011).
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
25. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519.
26. American Diabetes Association. Diabetic nephropathy (position statement). Diabetes Care 2002; 25: (Suppl. 1): S85-89.
27. Nolin TD. Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens 2008; 17: 555-559.
28. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009; 65: 757-773.
29. Harbourt DE, Fallon JK, Ito S, Baba T, Ritter JK, Glish GL, Smith PC. Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal Chem 2012; 84: 98-105.
30. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 2006; 21: 357-374.
31. Lohr JW, Willsky GR, Acara MA. Renal drug metabolism. Pharmacol Rev 1998; 50: 107-141.
32. Williams LR, Leggett RW. Reference values for resting blood flow to organs of man. Clin Phys Physiol Meas 1989; 10: 187-217.
33. Miners JO, Knights KM, Houston JB, Mackenzie PI. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 2006; 71: 1531-1539.
34. Ishii Y, Takeda S, Yamada H. Modulation of UDP-glucuronosyltransferase activity by protein-protein association. Drug Metab Rev 2010; 42: 145-158.